Nückel H - Search Results

1

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.

Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nückel H, Merkel O, Ghia P, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, Dyer MJ, Söderkvist P, Linderholm M, Oscier D, Tvaruzkova Z, Pospisilova S, Dührsen U, Greil R, Döhner H, Stilgenbauer S, Zenz T; European Research Initiative on CLL (ERIC). Benner A, et al. Among authors: nuckel h. Haematologica. 2014 Aug;99(8):1285-91. doi: 10.3324/haematol.2013.101170. Haematologica. 2014. PMID: 25082786 Free PMC article.

2

Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia.

Dürig J, Nückel H, Hüttmann A, Kruse E, Hölter T, Halfmeyer K, Führer A, Rudolph R, Kalhori N, Nusch A, Deaglio S, Malavasi F, Möröy T, Klein-Hitpass L, Dührsen U. Dürig J, et al. Among authors: nuckel h. Blood. 2003 Apr 1;101(7):2748-55. doi: 10.1182/blood-2002-09-2683. Epub 2002 Nov 27. Blood. 2003. PMID: 12456497 Free article.

3

Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas.

Nückel H, Dürig J, Dührsen U. Nückel H, et al. Ann Hematol. 2003 Aug;82(8):481-486. doi: 10.1007/s00277-003-0678-1. Epub 2003 Jun 21. Ann Hematol. 2003. PMID: 12910375

4

ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia.

Dürig J, Nückel H, Cremer M, Führer A, Halfmeyer K, Fandrey J, Möröy T, Klein-Hitpass L, Dührsen U. Dürig J, et al. Among authors: nuckel h. Leukemia. 2003 Dec;17(12):2426-34. doi: 10.1038/sj.leu.2403147. Leukemia. 2003. PMID: 14523469

5

The CC genotype of the C825T polymorphism of the G protein beta3 gene (GNB3) is associated with a high relapse rate in patients with chronic lymphocytic leukaemia.

Nückel H, Frey U, Aralh N, Dürig J, Dührsen U, Siffert W. Nückel H, et al. Leuk Lymphoma. 2003 Oct;44(10):1739-43. doi: 10.1080/1042819031000111017. Leuk Lymphoma. 2003. PMID: 14692527

6

1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcome.

Nückel H, Frey UH, Dürig J, Dührsen U, Siffert W. Nückel H, et al. Eur J Haematol. 2004 Apr;72(4):259-63. doi: 10.1111/j.0902-4441.2003.00210.x. Eur J Haematol. 2004. PMID: 15089763

7

Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva.

Nückel H, Meller D, Steuhl KP, Dührsen U. Nückel H, et al. Eur J Haematol. 2004 Oct;73(4):258-62. doi: 10.1111/j.1600-0609.2004.00299.x. Eur J Haematol. 2004. PMID: 15347312

8

Methylenetetrahydrofolate reductase (MTHFR) gene 677C>T and 1298A>C polymorphisms are associated with differential apoptosis of leukemic B cells in vitro and disease progression in chronic lymphocytic leukemia.

Nückel H, Frey UH, Dürig J, Dührsen U, Siffert W. Nückel H, et al. Leukemia. 2004 Nov;18(11):1816-23. doi: 10.1038/sj.leu.2403484. Leukemia. 2004. PMID: 15385937

9

HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia.

Nückel H, Rebmann V, Dürig J, Dührsen U, Grosse-Wilde H. Nückel H, et al. Blood. 2005 Feb 15;105(4):1694-8. doi: 10.1182/blood-2004-08-3335. Epub 2004 Oct 5. Blood. 2005. PMID: 15466928 Free article.

10

Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.

Nückel H, Frey UH, Röth A, Dührsen U, Siffert W. Nückel H, et al. Eur J Pharmacol. 2005 May 9;514(2-3):217-24. doi: 10.1016/j.ejphar.2005.03.024. Eur J Pharmacol. 2005. PMID: 15910809

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

72 results

Search Page